Our Mission
Our mission is to deliver flexible and comprehensive testing solutions for precision medicine diagnostics and pathology services to improve patient outcomes in cancer care.
Why Fulgent Oncology?
The team at Fulgent Oncology is committed to working side by side with every one of our clients. This is essential to developing strong and successful relationships and is our core way of doing business. We have collaborated with some of the top clinicians in our field who have assisted us in creating panels and report formatting. Our approach is simple: provide testing based on the specific needs of clinicians and their patients.
Precise diagnostics
Fulgent Oncology, a division of Fulgent Genetics, was created to support oncology practices by delivering clinically relevant and precise diagnostics in an efficient manner. By doing so, we aim to improve patient outcomes in cancer care
Technology-driven
As a global, technology-driven clinical diagnostics company, we are focused on redefining precision medicine solutions, and we strive to become the premier full-reference oncology and precision medical diagnostics provider in the U.S.
Your healthcare partner
At Fulgent Oncology, we partner with healthcare practices to support each patient's cancer journey from diagnosis to treatment guidance, prognosis, and monitoring.
Our History
Fulgent Oncology is part of Fulgent Genetics, a genetic testing company founded in 2011. We were the first clinical laboratory in the U.S. to offer copy number variation (CNV) detection using NGS technology, and we've continued to pursue excellence in precision medicine ever since.
We expanded our capabilities in 2021 through the acquisition of CSI Laboratories, a leader in anatomic pathology and hematology on the East coast with more than 25 years of experience. In 2022, we acquired Inform Diagnostics, a leading anatomic pathology and hematology laboratory on the West coast. As our companies have come together, we've harnessed our collective expertise to create a unique, comprehensive offering.
We expanded our capabilities in 2021 through the acquisition of CSI Laboratories, a leader in anatomic pathology and hematology on the East coast with more than 25 years of experience. In 2022, we acquired Inform Diagnostics, a leading anatomic pathology and hematology laboratory on the West coast. As our companies have come together, we've harnessed our collective expertise to create a unique, comprehensive offering.
